Cost‐effectiveness analysis of empagliflozin versus sitagliptin as
second‐line
therapy for treatment in patients with type 2 diabetes in the United States
Diabetes, Obesity and Metabolism(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要